ArticleInternational journal of nanomedicine2026
Ion‑Responsive in situ Gel of Quercetin‑Loaded PEGylated Liposomes for Anti‑inflammatory Treatment of Dry Eye Disease.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dry eye disease (DED) is a global health burden with limited effective and safe treatments. Quercetin (Qu) possesses potent anti-inflammatory and antioxidant activities, but its poor solubility and short half-life restrict ophthalmic use. Methods: Qu‑loaded PEGylated liposomes (Qu‑PL) were prepared by thin‑film hydration and incorporated into gellan gum to form an ion‑responsive in situ gel (Qu‑PL‑ISG). The formulation was characterized for particle size (PS), zeta potential (ZP), polydispersity index (PDI), encapsulation efficiency (EE), short-stability, in vitro release, cytotoxicity, ocular irritation, mucoadhesion, ocular surface retention, pharmacokinetics, and therapeutic efficacy in a BAC‑induced DED mouse model. Network pharmacology and molecular docking were used to generate testable hypotheses on possible mechanisms of Qu in DED. Results: Qu‑PL‑ISG had a PS of 173.33 ± 1.27 nm, a ZP of -46.87 ± 0.95 mV, and an EE of 88.85 ± 1.41%. It released 46% of Qu over 72 h and remained stable for 21 days at 4 °C, with no cytotoxicity or irritation. Compared with Qu‑PL, Qu‑PL‑ISG exhibited higher mucoadhesive force (3783.5 ± 125.2 vs. 1986.2 ± 145.7 dyne/cm Conclusion: Qu‑PL‑ISG is a safe, ion‑activated in situ gel that significantly enhances Qu bioavailability and anti‑inflammatory efficacy, showing promise for DED treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.